DOCSLIB.ORG

Manufacturers of Drugs Used to Treat Parasitic

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Manufacturers of Drugs Used to Treat Parasitic Page 1 of 2 BALANTIDIASIS (Balantidium coli) Drug Adult dosage Pediatric dosage Drug of choice: Tetracycline1,2 500 mg PO qid x 10d 40 mg/kg/d (max. 2 g) PO in 4 doses x 10d Alternative: Metronidazole1 750 mg PO tid x 5d 35-50 mg/kg/d PO in 3 doses x 5d OR Iodoquinol1,3 650 mg PO tid x 20d 30-40 mg/kg/d (max 2 g) PO in 3 doses x 20d 1. Not FDA-approved for this indication. 2. Use of tetracyclines is contraindicated in pregnancy and in children <8 years old. Tetracycline should be taken 1 hour before or 2 hours after meals and/or dairy products. 3. Iodoquinol should be taken after meals. Information provided by The Medical Letter. For a copy of the entire Drugs for Parasitic Infections article, go to: www.medicalletter.org/parasitic_cdc MANUFACTURERS OF DRUGS USED TO TREAT PARASITIC INFECTIONS albendazole – Albenza (GlaxoSmithKline) lumefantrine/artemether – Coartem, Riamet Albenza (GlaxoSmithKline) – albendazole (Novartis) Alinia (Romark) – nitazoxanide Malarone (GlaxoSmithKline) – AmBisome (Gilead) – amphotericin B, liposomal atovaquone/proguanil amphotericin B – Fungizone (Apothecon), others malathion – Ovide (Medicis) amphotericin B, liposomal – AmBisome (Gilead) mebendazole – Vermox (McNeil), others Ancobon (Valeant) – flucytosine mefloquine – Lariam (Roche) § Antiminth (Pfizer) – pyrantel pamoate § meglumine antimonate – Glucantime (Aventis, • Aralen (Sanofi) – chloroquine HCl and chloroquine France) phosphate † melarsoprol – Mel-B § artemether – Artenam (Arenco, Belgium) † Mel-B – melarsoprol § artemether/lumefantrine – Coartem, Riamet Mepron (GlaxoSmithKline) – atovaquone (Novartis) metronidazole – Flagyl (Pfizer), others § Artenam (Arenco, Belgium) – artemether § miconazole – Monistat i.v. § artesunate – (Guilin No. 1 Factory, People’s § miltefosine – Impavido (Zentaris, Germany) Republic of China) § Monistat i.v. – miconazole atovaquone – Mepron (GlaxoSmithKline) NebuPent (Fujisawa) – pentamidine isethionate atovaquone/proguanil – Malarone § niclosamide – Yomesan (Bayer, Germany) (GlaxoSmithKline) † nifurtimox – Lampit (Bayer, Germany) azithromycin – Zithromax (Pfizer), others nitazoxanide – Alinia (Romark) • Bactrim (Roche) – TMP/Sulfa Nix (GlaxoSmithKline) – permethrin § benznidazole – Rochagan (Brazil) • Nizoral (Janssen) – ketoconazole • Biaxin (Abbott) – clarithromycin § ornidazole – Tiberal (Roche, France) § Biltricide (Bayer) – praziquantel Ornidyl (Aventis) – eflornithine † bithionol – Bitin (Tanabe, Japan) (Difluoromethylornithine, DFMO) † Bitin (Tanabe, Japan) – bithionol Ovide (Medicis) – malathion § Brolene (Aventis, Canada) – propamidine § oxamniquine – Vansil (Pfizer) isethionate § Paludrine (AstraZeneca, United Kingdom) – proguanil chloroquine HCl and chloroquine phosphate – paromomycin – Humatin (Monarch); Leshcutan Aralen (Sanofi), others (Teva, Israel; topical formulation not available clarithromycin – Biaxin (Abbott), others in US) • Cleocin (Pfizer) – clindamycin Pentam 300 (Fujisawa) – pentamidine isethionate clindamycin – Cleocin (Pfizer), others pentamidine isethionate – Pentam 300 (Fujisawa), Coartem (Novartis) – artemether/lumefantrine NebuPent (Fujisawa) crotamiton – Eurax (Westwood-Squibb) † Pentostam (GlaxoSmithKline, United Kingdom) – dapsone – (Jacobus) sodium stibogluconate § Daraprim (GlaxoSmithKline) – pyrimethamine USP permethrin – Nix (GlaxoSmithKline), Elimite † diethylcarbamazine citrate (DEC) – Hetrazan (Allergan) • Difluca\n (Pfizer) – fluconazole § praziquantel – Biltricide (Bayer) § diloxanide furoate – Furamide (Boots, United primaquine phosphate USP Kingdom) § proguanil – Paludrine (AstraZeneca, United Kingdom) doxycycline – Vibramycin (Pfizer), others proguanil/atovaquone – Malarone eflornithine (Difluoromethylornithine, DFMO) – (GlaxoSmithKline) Ornidyl (Aventis) § propamidine isethionate – Brolene (Aventis, § Egaten (Novartis) – triclabendazole Canada) Elimite (Allergan) – permethrin § pyrantel pamoate – Antiminth (Pfizer) Ergamisol (Janssen) – levamisole pyrethrins and piperonyl butoxide – RID (Pfizer), Eurax (Westwood-Squibb) – crotamiton others • Flagyl (Pfizer) – metronidazole § pyrimethamine USP – Daraprim (GlaxoSmithKline) § Flisint (Sanofi-Aventis, France) – fumagillin Qualaquin – quinine sulfate (Mutual Pharmaceutical fluconazole – Diflucan (Pfizer), others Co/AR Scientific) flucytosine – Ancobon (Valeant) quinacrine § fumagillin – Flisint (Sanofi-Aventis, France) * quinidine gluconate (Eli Lilly) • Fungizone (Apothecon) – amphotericin § quinine dihydrochloride § Furamide (Boots, United Kingdom) – diloxanide quinine sulfate – Qualaquin (Mutual Pharmaceutical furoate Co/AR Scientific) § furazolidone – Furozone (Roberts) Riamet (Novartis) – artemether/lumefantrine § Furozone (Roberts) – furazolidone • RID (Pfizer) – pyrethrins and piperonyl butoxide † Germanin (Bayer, Germany) – suramin sodium • Rifadin (Aventis) – rifampin § Glucantime (Aventis, France) – meglumine rifampin – Rifadin (Aventis), others antimonate § Rochagan (Brazil) – benznidazole † Hetrazan – diethylcarbamazine citrate (DEC) * Rovamycine (Aventis) – spiramycin Humatin (Monarch) – paromomycin † sodium stibogluconate – Pentostam § Impavido (Zentaris, Germany) – miltefosine (GlaxoSmithKline, United Kingdom) iodoquinol – Yodoxin (Glenwood), others * spiramycin – Rovamycine (Aventis) itraconazole – Sporanox (Janssen-Ortho), others • Sporanox (Janssen-Ortho) – itraconazole ivermectin – Stromectol (Merck) Stromectol (Merck) – ivermectin ketoconazole – Nizoral (Janssen), others sulfadiazine – (Eon) † Lampit (Bayer, Germany) – nifurtimox † suramin sodium – Germanin (Bayer, Germany) Lariam (Roche) – mefloquine § Tiberal (Roche, France) – ornidazole § Leshcutan (Teva, Israel) – topical paromomycin Tindamax (Mission) – tinidazole levamisole – Ergamisol (Janssen) tinidazole – Tindamax (Mission) (continued) Page 2 of 2 TMP/Sulfa – Bactrim (Roche), others • Vibramycin (Pfizer) – doxycycline § triclabendazole – Egaten (Novartis) • Yodoxin (Glenwood) – iodoquinol § Vansil (Pfizer) – oxamniquine § Yomesan (Bayer, Germany) – niclosamide • Vermox (McNeil) – mebendazole • Zithromax (Pfizer) – azithromycin * Available in the US only from the manufacturer. § Not available commercially. It may be obtained through compounding pharmacies such as Panorama Compounding Pharmacy, 6744 Balboa Blvd, Van Nuys, CA 91406 (800-247-9767) or Medical Center Pharmacy, New Haven, CT (203-688-6816). Other com- pounding pharmacies may be found through the National Association of Compounding Pharmacies (800-687-7850) or the Professional Compounding Centers of America (800-331-2498, www.pccarx.com). † Available from the CDC Drug Service, Centers for Disease Control and Prevention, Atlanta, Georgia 30333; 404-639-3670 (evenings, weekends, or holidays: 770-488-7100). • Also available generically. Information provided by The Medical Letter. For a copy of the entire Drugs for Parasitic Infections article, go to: www.medicalletter.org/parasitic_cdc.
Load more

Recommended publications
  • Balantidium Coli
    GLOBAL WATER PATHOGEN PROJECT PART THREE. SPECIFIC EXCRETED PATHOGENS: ENVIRONMENTAL AND EPIDEMIOLOGY ASPECTS BALANTIDIUM COLI Francisco Ponce-Gordo Complutense University Madrid, Spain Kateřina Jirků-Pomajbíková Institute of Parasitology Biology Centre, ASCR, v.v.i. Budweis, Czech Republic Copyright: This publication is available in Open Access under the Attribution-ShareAlike 3.0 IGO (CC-BY-SA 3.0 IGO) license (http://creativecommons.org/licenses/by-sa/3.0/igo). By using the content of this publication, the users accept to be bound by the terms of use of the UNESCO Open Access Repository (http://www.unesco.org/openaccess/terms-use-ccbysa-en). Disclaimer: The designations employed and the presentation of material throughout this publication do not imply the expression of any opinion whatsoever on the part of UNESCO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. The ideas and opinions expressed in this publication are those of the authors; they are not necessarily those of UNESCO and do not commit the Organization. Citation: Ponce-Gordo, F., Jirků-Pomajbíková, K. 2017. Balantidium coli. In: J.B. Rose and B. Jiménez-Cisneros, (eds) Global Water Pathogens Project. http://www.waterpathogens.org (R. Fayer and W. Jakubowski, (eds) Part 3 Protists) http://www.waterpathogens.org/book/balantidium-coli Michigan State University, E. Lansing, MI, UNESCO. Acknowledgements: K.R.L. Young, Project Design editor; Website Design (http://www.agroknow.com) Published: January 15, 2015, 11:50 am, Updated: October 18, 2017, 5:43 pm Balantidium coli Summary 1.1.1 Global distribution Balantidium coli is reported worldwide although it is To date, Balantidium coli is the only ciliate protozoan more common in temperate and tropical regions (Areán and reported to infect the gastrointestinal track of humans.
    [Show full text]
  • The Intestinal Protozoa
    The Intestinal Protozoa A. Introduction 1. The Phylum Protozoa is classified into four major subdivisions according to the methods of locomotion and reproduction. a. The amoebae (Superclass Sarcodina, Class Rhizopodea move by means of pseudopodia and reproduce exclusively by asexual binary division. b. The flagellates (Superclass Mastigophora, Class Zoomasitgophorea) typically move by long, whiplike flagella and reproduce by binary fission. c. The ciliates (Subphylum Ciliophora, Class Ciliata) are propelled by rows of cilia that beat with a synchronized wavelike motion. d. The sporozoans (Subphylum Sporozoa) lack specialized organelles of motility but have a unique type of life cycle, alternating between sexual and asexual reproductive cycles (alternation of generations). e. Number of species - there are about 45,000 protozoan species; around 8000 are parasitic, and around 25 species are important to humans. 2. Diagnosis - must learn to differentiate between the harmless and the medically important. This is most often based upon the morphology of respective organisms. 3. Transmission - mostly person-to-person, via fecal-oral route; fecally contaminated food or water important (organisms remain viable for around 30 days in cool moist environment with few bacteria; other means of transmission include sexual, insects, animals (zoonoses). B. Structures 1. trophozoite - the motile vegetative stage; multiplies via binary fission; colonizes host. 2. cyst - the inactive, non-motile, infective stage; survives the environment due to the presence of a cyst wall. 3. nuclear structure - important in the identification of organisms and species differentiation. 4. diagnostic features a. size - helpful in identifying organisms; must have calibrated objectives on the microscope in order to measure accurately.
    [Show full text]
  • Antibiotic Therapy of Cholera in Children,*
    Bull. Org. mond. Santo 1967, 37, 529-538 Bull. Wld filth Org. Antibiotic Therapy of Cholera in Children,* JOHN LINDENBAUM,1 WILLIAM B. GREENOUGH 2 & M. R. ISLAM In a controlled trial of the effects of oral antibiotics in treating cholera in children in Dacca, East Pakistan, tetracycline was the most effective of 4 antibiotics tested in reducing stool volume, intravenous fluid requirement, and the duration of diarrhoea and positive stool culture. Increasing the duration of tetracycline therapy from 2 to 4 days, or increasing the total dose administered, resulted in shorter duration ofpositive culture, but did not affect stool volume or duration ofdiarrhoea. Only I % of the children receiving tetracycline had diarrhoea for more than 4 days. Tetracycline was significantly more effective than intravenous fluid therapy alone, regardless of severity of disease. Chloramphenicol, while also effective, was inferior to tetracycline. Streptomycin and paromomycin exerted little or no effect on the course of illness or duration of positive culture. Therapeutic failures with these drugs were not due to the development ofbacterial resistance. From these findings, tetracycline appears to be the drug of choice against Vibrio cholerae infection in children. Oral therapy for 48 hours is effective clinically, but is associated with 20% bacteriological relapses when the drug is discontinued; it is not known whether extending the therapy for a week or more would eliminate such relapses. In recent years several groups have conducted replacement was compared with treatment with clinical trials of antibiotic therapy in adult patients intravenous fluids only. with cholera (Greenough et al., 1964; Carpenter et al., 1966; Uylangco et al., 1965, 1966; Kobari, METHODS AND MATERIALS 1965; Lindenbaum et al., 1967).
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Case 2:17-Cv-03768-CMR Document 3-1 Filed 10/31/17 Page 1 of 243
    Case 2:17-cv-03768-CMR Document 3-1 Filed 10/31/17 Page 1 of 243 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF PENNSYLVANIA IN RE: GENERIC PHARMACEUTICALS MDL 2724 PRICING ANTITRUST LITIGATION 16-MD-2724 ____________________________________ HON. CYNTHIA M. RUFE IN RE: STATE ATTORNEYS GENERAL LEAD CASE: 16-AG-27240 CASES ____________________________________ THIS DOCUMENT RELATES TO: ALL STATE ATTORNEYS GENERAL ACTIONS November __, 2017 ____________________________________ THE STATE OF CONNECTICUT; THE STATE OF ALABAMA; PLAINTIFF STATES' [PROPOSED] THE STATE OF ALASKA; CONSOLIDATED AMENDED THE STATE OF ARIZONA; COMPLAINT THE STATE OF ARKANSAS; THE STATE OF CALIFORNIA; THE STATE OF COLORADO; THE DISTRICT OF COLUMBIA; THE STATE OF DELAWARE; Public Version THE STATE OF FLORIDA; THE STATE OF HAWAII; THE STATE OF IDAHO; THE STATE OF ILLINOIS; THE STATE OF INDIANA; THE STATE OF IOWA; THE STATE OF KANSAS; THE COMMONWEALTH OF KENTUCKY; THE STATE OF LOUISIANA; THE STATE OF MAINE; THE STATE OF MARYLAND; THE COMMONWEALTH OF MASSACHUSETTS; THE STATE OF MICHIGAN; THE STATE OF MINNESOTA; THE STATE OF MISSISSIPPI; THE STATE OF MISSOURI; THE STATE OF MONTANA; THE STATE OF NEBRASKA; THE STATE OF NEVADA; Case 2:17-cv-03768-CMR Document 3-1 Filed 10/31/17 Page 2 of 243 THE STATE OF NEW HAMPSHIRE; THE STATE OF NEW JERSEY; THE STATE OF NEW MEXICO; THE STATE OF NEW YORK; THE STATE OF NORTH CAROLINA; THE STATE OF NORTH DAKOTA; THE STATE OF OHIO; THE STATE OF OKLAHOMA; THE STATE OF OREGON; THE COMMONWEALTH OF PENNSYLVANIA; THE COMMONWEALTH OF PUERTO RICO; THE STATE OF SOUTH CAROLINA; THE STATE OF TENNESSEE; THE STATE OF UTAH; THE STATE OF VERMONT; THE COMMONWEALTH OF VIRGINIA; THE STATE OF WASHINGTON; THE STATE OF WEST VIRGINIA; THE STATE OF WISCONSIN; v.
    [Show full text]
  • WO 2012/148799 Al 1 November 2012 (01.11.2012) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/148799 Al 1 November 2012 (01.11.2012) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/107 (2006.01) A61K 9/00 (2006.01) kind of national protection available): AE, AG, AL, AM, A 61 47/10 (2006.0V) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, PCT/US2012/034361 HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, (22) International Filing Date: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 20 April 2012 (20.04.2012) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (26) Publication Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/480,259 28 April 201 1 (28.04.201 1) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (71) Applicant (for all designated States except US): BOARD UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, OF REGENTS, THE UNIVERSITY OF TEXAS SYS¬ TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, TEM [US/US]; 201 West 7th St., Austin, TX 78701 (US).
    [Show full text]
  • SNF Mobility Model: ICD-10 HCC Crosswalk, V. 3.0.1
    The mapping below corresponds to NQF #2634 and NQF #2636. HCC # ICD-10 Code ICD-10 Code Category This is a filter ceThis is a filter cellThis is a filter cell 3 A0101 Typhoid meningitis 3 A0221 Salmonella meningitis 3 A066 Amebic brain abscess 3 A170 Tuberculous meningitis 3 A171 Meningeal tuberculoma 3 A1781 Tuberculoma of brain and spinal cord 3 A1782 Tuberculous meningoencephalitis 3 A1783 Tuberculous neuritis 3 A1789 Other tuberculosis of nervous system 3 A179 Tuberculosis of nervous system, unspecified 3 A203 Plague meningitis 3 A2781 Aseptic meningitis in leptospirosis 3 A3211 Listerial meningitis 3 A3212 Listerial meningoencephalitis 3 A34 Obstetrical tetanus 3 A35 Other tetanus 3 A390 Meningococcal meningitis 3 A3981 Meningococcal encephalitis 3 A4281 Actinomycotic meningitis 3 A4282 Actinomycotic encephalitis 3 A5040 Late congenital neurosyphilis, unspecified 3 A5041 Late congenital syphilitic meningitis 3 A5042 Late congenital syphilitic encephalitis 3 A5043 Late congenital syphilitic polyneuropathy 3 A5044 Late congenital syphilitic optic nerve atrophy 3 A5045 Juvenile general paresis 3 A5049 Other late congenital neurosyphilis 3 A5141 Secondary syphilitic meningitis 3 A5210 Symptomatic neurosyphilis, unspecified 3 A5211 Tabes dorsalis 3 A5212 Other cerebrospinal syphilis 3 A5213 Late syphilitic meningitis 3 A5214 Late syphilitic encephalitis 3 A5215 Late syphilitic neuropathy 3 A5216 Charcot's arthropathy (tabetic) 3 A5217 General paresis 3 A5219 Other symptomatic neurosyphilis 3 A522 Asymptomatic neurosyphilis 3 A523 Neurosyphilis,
    [Show full text]
  • Enteric Protozoa in the Developed World: a Public Health Perspective
    Enteric Protozoa in the Developed World: a Public Health Perspective Stephanie M. Fletcher,a Damien Stark,b,c John Harkness,b,c and John Ellisa,b The ithree Institute, University of Technology Sydney, Sydney, NSW, Australiaa; School of Medical and Molecular Biosciences, University of Technology Sydney, Sydney, NSW, Australiab; and St. Vincent’s Hospital, Sydney, Division of Microbiology, SydPath, Darlinghurst, NSW, Australiac INTRODUCTION ............................................................................................................................................420 Distribution in Developed Countries .....................................................................................................................421 EPIDEMIOLOGY, DIAGNOSIS, AND TREATMENT ..........................................................................................................421 Cryptosporidium Species..................................................................................................................................421 Dientamoeba fragilis ......................................................................................................................................427 Entamoeba Species.......................................................................................................................................427 Giardia intestinalis.........................................................................................................................................429 Cyclospora cayetanensis...................................................................................................................................430
    [Show full text]
  • Belgian Veterinary Surveillance of Antibacterial Consumption National
    Belgian Veterinary Surveillance of Antibacterial Consumption National consumption report 2020 Publication : 22 June 2021 1 SUMMARY This annual BelVet-SAC report is now published for the 12th time and describes the antimicrobial use (AMU) in animals in Belgium in 2020 and the evolution since 2011. For the third year this report combines sales data (collected at the level of the wholesalers-distributors and the compound feed producers) and usage data (collected at farm level). This allows to dig deeper into AMU at species and farm level in Belgium. With a consumption of 87,6 mg antibacterial compounds/kg biomass an increase of +0.2% is seen in 2020 in comparison to 2019. The increase seen in 2020 is spread over both pharmaceuticals (+0.2%) and antibacterial premixes (+4.0%). This unfortunately marks the end of a successful reduction in antibacterial product sales that was seen over the last 6 years resulting in a cumulative reduction of -40,2% since 2011. The gap seen in the coverage of the sales data with the Sanitel-Med collected usage data increased substantially compared to 2019, meaning continuous efforts need to be taken to ensure completeness of the collected usage data. When looking at the evolution in the number of treatment days (BD100) at the species level, as calculated from the SANITEL- MED use data, use increased in poultry (+5,0%) and veal calves (+1,9%), while it decreased in pigs (-3,1%). However, the numerator data for this indicator remain to be updated for 2020, potentially influencing the reliability of the result.
    [Show full text]
  • Comparative Genomics of the Major Parasitic Worms
    Comparative genomics of the major parasitic worms International Helminth Genomes Consortium Supplementary Information Introduction ............................................................................................................................... 4 Contributions from Consortium members ..................................................................................... 5 Methods .................................................................................................................................... 6 1 Sample collection and preparation ................................................................................................................. 6 2.1 Data production, Wellcome Trust Sanger Institute (WTSI) ........................................................................ 12 DNA template preparation and sequencing................................................................................................. 12 Genome assembly ........................................................................................................................................ 13 Assembly QC ................................................................................................................................................. 14 Gene prediction ............................................................................................................................................ 15 Contamination screening ............................................................................................................................
    [Show full text]
  • (ESVAC) Web-Based Sales and Animal Population
    16 July 2019 EMA/210691/2015-Rev.2 Veterinary Medicines Division European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) Sales Data and Animal Population Data Collection Protocol (version 3) Superseded by a new version Superseded Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. Table of content 1. Introduction ....................................................................................................................... 3 1.1. Terms of reference ........................................................................................................... 3 1.2. Approach ........................................................................................................................ 3 1.3. Target groups of the protocol and templates ......................................................................... 4 1.4. Organization of the ESVAC project ...................................................................................... 4 1.5. Web based delivery of data ................................................................................................ 5 2. ESVAC sales data ............................................................................................................... 5 2.1.
    [Show full text]
  • Balantidiasis in an Asiatic Elephant and Its Therapeutic Management
    J Parasit Dis (Apr-June 2019) 43(2):186–189 https://doi.org/10.1007/s12639-018-1072-1 ORIGINAL ARTICLE Balantidiasis in an Asiatic elephant and its therapeutic management 1 2 1,3 1 N. Thakur • R. Suresh • G. E. Chethan • K. Mahendran Received: 8 October 2018 / Accepted: 12 December 2018 / Published online: 19 December 2018 Ó Indian Society for Parasitology 2018 Abstract A 14 years old female Asiatic elephant was Introduction presented to the hospital with a history of mucoid watery diarrhea, inappetence and lethargy. Clinical examination The causes and patho-physiologic features of chronic revealed normal body temperature (98.2 °F), tachycardia diarrhea in animals still remains a mystery in most cases. (42 bpm), eupnoea (14/min), congested mucous membrane The identification of the specific cause is essential for and dehydration. Haemato-biochemical parameters are rational treatment of clinical cases and also for prevention well within the range. Microscopic examination of faecal and control of the disease. Balantidiasis is an infectious sample revealed presence of live, motile and pear shaped disease caused by the protozoa Balantidium coli and is ciliated Balantidium coli protozoa. Based on clinical and characterized by chronic diarrhea (Islam et al. 2000; laboratory examination, the condition was diagnosed as Randhawa et al. 2010). Although the disease condition balantidiasis. The animal was treated with Tab. Metron- reported from different parts of the world, high prevalence idazole (10 mg/Kg, PO, BID) for 5 days. Supportive noticed in subtropical and tropical regions (Sampurna treatment was done with antacids, hepatoprotectants and 2007). Balantidium coli is a large, ciliated protozoan par- multivitamin supplements.
    [Show full text]